medigraphic.com

2015, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (6)

Expression of TREM-1 in patients with invasive cervical cancer and precursor lesions

Anaya-Prado R, Norzgaray-Ibarra FG, Bravo-Cuellar A, Pérez-Avila CE, Schadegg-Peña D, Anaya-Fernández MM

Language: Spanish
References: 16
Page: 722-727
PDF size: 168.30 Kb.


ABSTRACT

Background: It has been shown that the TREM-1 glycoprotein belongs to the immunoglobulin superfamily that induces secretion of various proinflammatory cytokines. The aim of this study was to measure the expression of TREM-1 in patients with cervical cancer.
Methods: In this cross-sectional study we included four groups of patients: GI: women with low-grade squamous intraepithelial lesion (IL) (n = 15 p / g); GII: patients with high-grade squamous IL (n = 9 w / g); GIII: patients with invasive cervical cancer (n = 9 p / g) and GIV: healthy patients (n = 15 p / g). In all patients the expression of TREM-1 and the Average Fluorescence Index (AFI) in neutrophils and monocytes were measured, as well as levels of leukocytes, neutrophils and monocytes. We used Student’s t test for independent samples. For these variables, we applied Mann-Whitney rank-sum, ANOVA, and Tukey tests. Chi square test was used for qualitative variables.
Results: The percentages of TREM-1 expression in neutrophils and monocytes, plus the AFI in neutrophils in the 4 groups was not significantly different. The AFI of TREM-1 in monocytes was significantly different when comparing group II and group III versus group IV (p ‹ 0.02). There was also no significant difference when comparing the mean values of leukocytes, neutrophils and monocytes in the different groups.
Conclusion: This study shows increased expression of TREM-1 in monocytes from patients with advanced cancer.


REFERENCES

  1. Kalima M, Lishimpi K, Meza JL, et al. Observed and Expected Incidence of Cervical Cancer in Lusaka and the Southern and Western Provinces of Zambia, 2007 to 2012. Int J Gynecol Cancer 2015;25(1):1-8.

  2. Lim S, Lee CM, Park JM, Jung SY, Lee KB. An association between preoperative anemia and poor prognostic factors and decreased survival in early stage cervical cancer patients. Obstet Gynecol Sci 2014;57(6):471-477.

  3. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensos guidelines for the management of abdominal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121(4):829-46.

  4. Eduardo L. Franco, Eliane Duarte-Franco, Alex Ferenczy. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001;164(7):164.

  5. L. Richeldi, M. Mariani, M. Losi, F. Maselli, L. Corbetta, C. Buonsanti, M. Colonna, F. Sinigaglia, Panina-Bordignon, L.M. Fabbri. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J 2004;24(2): 247-250.

  6. Lanier, L. L. 2001. Face off — the interplay between activating and inhibitory immune receptors. Curr Opin Immunol. 2001;13(3):326-331.

  7. Axel Bouchon, Jes Dietrich, and Marco Colonna. Cutting Edge: Infl ammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes. J Immunol 2000; 164(10):4991-5.

  8. Chi Ho, Wei-Yu Liao, Cheng-Yi Wang, Yin-Hsiu Lu, Hsin-Yi Huang, Hsuan-Yu Chen4, Wing-Kai Chan, Huei-Wen Chen, and Pan-Chyr Yang. TREM-1 Expression in Tumor-associated Macrophagesand Clinical Outcome in Lung Cancer. Chao- Am J Respir Crit Care Med 2008;177(7):763-770.

  9. Gibot S, Cravoisy A, Levy B, Bene M-C, Faure G, Bollaert P-E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350:451-458.

  10. Gibot S, Kolopp-Sarda M-N, Bene MC, Cravoisy A, Levy B, Faure GC, Bollaert P-E. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004;141(1):9-15.

  11. Gibot S, Kolopp-Sarda M-N, Bene M-C, Bollaert P-E, Lozniewski A, Mory F, Levy B, Faure GC. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the infl ammatory response in murine sepsis. J Exp Med 2004;200(11):1419-1426.

  12. Gonzalez-Roldan N, Ferat-Osorio E, Aduna-Vicente R, Wong-Baeza I,Esquivel-Callejas N, Astudillo-de la Vega H, Sanchez-Fernandez P, Arriaga-Pizano L, Villasis-Keever MA, Lopez-Macias C, et al. Expression of triggering receptor on myeloid cell 1 and histocompatibility complex molecules in sepsis and major abdominal surgery. World J Gastroenterol 2005;11(47):7473-7479.

  13. Koussoulas V, Vassiliou S, Demonakou M, Tassias G, Giamarellos- Bourboulis EJ, Mouktaroudi M, Giamarellou H, Barbatzas C.Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. Eur J Gastroenterol Hepatol 2006;18(4): 375-379.

  14. Wang DY, Qin RY, Liu ZR, Gupta MK, Chang Q. Expression of TREM-1 mRNA in acute pancreatitis. World J Gastroenterol 2004;10(18):2744-2746.

  15. Amr M. Mahdy, Damon A. Lowes, Helen F. Galley, Jane E. Bruce, and Nigel R. Webster. Production of Soluble Triggering Receptor Expressed on Myeloid Cells by Lipopolysaccharide-Stimulated Human Neutrophils Involves De Novo Protein Synthesis. Clinical and vaccine inmunology, 2006:13(4):492-495.

  16. Apgar BS, Zoschnick L, Wright TC. The Bethesda System terminology. Am Fam Physician 2003;68 (10):1992-8.




2020     |     www.medigraphic.com